SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-228076
Filing Date
2023-09-05
Accepted
2023-09-05 07:06:58
Documents
18
Period of Report
2023-08-31
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d437285d8k.htm   iXBRL 8-K 33319
2 EX-10.1 d437285dex101.htm EX-10.1 69780
3 EX-99.1 d437285dex991.htm EX-99.1 15201
8 GRAPHIC g437285dsp01.jpg GRAPHIC 8407
9 GRAPHIC g437285dsp11.jpg GRAPHIC 5786
10 GRAPHIC g437285dsp7.jpg GRAPHIC 7290
  Complete submission text file 0001193125-23-228076.txt   327914

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA agle-20230831.xsd EX-101.SCH 3216
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE agle-20230831_def.xml EX-101.DEF 13745
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE agle-20230831_lab.xml EX-101.LAB 22637
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE agle-20230831_pre.xml EX-101.PRE 14561
12 EXTRACTED XBRL INSTANCE DOCUMENT d437285d8k_htm.xml XML 5331
Mailing Address 221 CRESCENT STREET BUILDING 17, SUITE 102B WALTHAM MA 02453
Business Address 221 CRESCENT STREET BUILDING 17, SUITE 102B WALTHAM MA 02453 6176515940
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

IRS No.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37722 | Film No.: 231234118
SIC: 2834 Pharmaceutical Preparations